Sanofi's Dupixent sales grow 45 percent in Q1

The sales for eczema drug Dupixent from Sanofi are growing steadily. During the year's first quarter, sales have increased by more than 45 percent.

Sanofi CEO Paul Hudson

Sales for Sanofi's major blockbuster drug Dupixent are mainly fueled by its use as a treatment for atopical dermatitis, but the drug's other approved indications are also gaining ground.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs